BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

RETROPHIN, INC. — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

RETROPHIN, INC.

via COVE STRATEGIES

3rd Quarter (July 1 - Sep 30) · 2019Posted Oct 21, 2019Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: RETROPHIN, INC.
Description: Biopharmaceutical Company
Location: California · United States of America

Registrant

Firm: COVE STRATEGIES
Description: Lobbying firm
Location: Alexandria, Virginia, United States of America

Lobbying activities

1 issue

Pharmacy
S.340 - CREATES Act of 2019 The Orphan Drug Act Drug pricing
LobbyistsANGELA FLOOD
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP)

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.